These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 2615728

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuous nasogastric administration of activated charcoal for the treatment of theophylline intoxication.
    Ohning BL, Reed MD, Blumer JL.
    Pediatr Pharmacol (New York); 1986; 5(4):241-5. PubMed ID: 3737269
    [Abstract] [Full Text] [Related]

  • 7. Severe theophylline intoxication: a delay in charcoal haemoperfusion solved by oral activated charcoal.
    Rutten J, van den Berg B, van Gelder T, van Saase J.
    Nephrol Dial Transplant; 2005 Dec; 20(12):2868-9. PubMed ID: 16115857
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Gastrointestinal transit times of cathartics combined with charcoal.
    Krenzelok EP, Keller R, Stewart RD.
    Ann Emerg Med; 1985 Dec; 14(12):1152-5. PubMed ID: 4061985
    [Abstract] [Full Text] [Related]

  • 11. A comparison of cathartics in pediatric ingestions.
    James LP, Nichols MH, King WD.
    Pediatrics; 1995 Aug; 96(2 Pt 1):235-8. PubMed ID: 7630676
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of ipecac and activated charcoal/cathartic. Prevention of salicylate absorption in a simulated overdose.
    Curtis RA, Barone J, Giacona N.
    Arch Intern Med; 1984 Jan; 144(1):48-52. PubMed ID: 6140906
    [Abstract] [Full Text] [Related]

  • 13. [Severe neurologic complications secondary to poisoning by slow-release theophylline].
    Carpentier F, Pison C, Barnoud D, Guignier M, Paramelle B.
    Rev Pneumol Clin; 1987 Jan; 43(4):182-5. PubMed ID: 3671969
    [Abstract] [Full Text] [Related]

  • 14. Model for theophylline overdose treatment with oral activated charcoal.
    Radomski L, Park GD, Goldberg MJ, Spector R, Johnson GF, Quee CK.
    Clin Pharmacol Ther; 1984 Mar; 35(3):402-8. PubMed ID: 6697647
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The frequency of complications associated with the use of multiple-dose activated charcoal.
    Dorrington CL, Johnson DW, Brant R, Multiple Dose Activated Charcoal Complication Study Group.
    Ann Emerg Med; 2003 Mar; 41(3):370-7. PubMed ID: 12605204
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of theophylline toxicity with oral activated charcoal.
    Sessler CN, Glauser FL, Cooper KR.
    Chest; 1985 Mar; 87(3):325-9. PubMed ID: 3971756
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.